Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trumenba (rLP2086) in healthy children and adolescents (8-14 years)
NCT00387725Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2006
- Primary completion
- Jan 2008
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B vaccine in meningococcal disease (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2, Percentage of Participants With Seroconversion in rLP2086 Specific SBA Titer 1 Month After Dose 3 and 1 more. Started Nov 2006; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00387725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387725.